Paroxysmal nocturnal hemoglobinuria: Where we stand

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by a complement-mediated intravascular hemolysis due to a genetic defect.
• Historically, PNH therapy relied on terminal complement inhibitors, with limited efficacy and side effects.
• The pathophysiology involves complement dysregulation leading to thrombosis and other severe complications.

Purpose of the Study:

• To provide a comprehensive overview of the evolution of PNH therapeutics.
• To discuss current and emerging treatment strategies targeting the complement cascade.
• To highlight the impact of new therapies on patient outcomes and disease management.

Main Methods:

• Review of historical and recent therapeutic approaches for PNH.
• Analysis of the complement cascade's role in PNH pathophysiology.
• Focus on approved and investigational complement inhibitors.

Main Results:

• The advent of proximal complement inhibitors, such as C3 inhibitors, marks a significant advancement.
• Newer therapies offer improved efficacy and potentially reduced side effect profiles compared to older treatments.
• Ongoing research aims to further refine treatment strategies and address unmet needs.

Conclusions:

• The therapeutic landscape for PNH has dramatically shifted towards targeting proximal complement pathways.
• Continuous scientific focus is essential for optimizing PNH treatment, minimizing side effects, and ensuring global accessibility.
• Future research should prioritize developing safe, effective, and widely available therapies for all PNH patients.